Antidepressant therapy in complex treatment of painful diabetic polyneuropathy

Aims.
Comparative efficiency and safety analysis of antidepressant agents from different pharmacological classes (pipofezine and venlafaxine)in combination with carbamazepine for treatment of neuropathic pain (NP) in patients with diabetic polyneuropathy (DP).
Materials and methods.
We examined 21 male and 27 female patients with painful DP (mean age 54.3?14.2 years; mean duration ofdiabetes mellitus (DM) 8.9?5.1 years; mean duration of DP - 3.8?2.1 years). DP was diagnosed clinically and by electromyographymethod. Pain syndrome was assessed with DN4 questionnaire, visual analogue scale (VAS) and McGill Pain Questionnaire. Psycho-vegetative status was evaluated by Spielberger test with reactive and personal anxiety (RA and PA) assessment and Beck depressioninventory. All patients received symptomatic pharmacotherapy with anticonvulsant and antidepressant agent. First group (DP-1)included 23 patients on carbamazepin and pipofezine. Second group (DP-2) included 25 patients on carbamazepin and venlafaxine.
Results.
Following treatment, pain syndrome was completely compensated in 8.7% of patients from DP-1 group and 12.5% from DP-2.Decrease in pain intensity?50% from initial level was achieved in 73.9% (DP-1) and 75% (DP-2) of cases. Mean pain intensityaccording to VAS reduced from 5.2?2.1 points to 2.3?1.4 points (DP-1) and from 5.8?2.3 points (DP-2) with equal statistical significance(p<0.001). Moreover, both groups were characterized by significant decrease in all indexes of McGill Pain Questionnaire.Patients from both groups showed improvement in autonomic disorders, depression, RA and PA. DP-1 reported lower rate of side effectsfrom the treatment. Predictors of positive treatment outcome (complete compensation or pain intensity reduction?50%) were found tobe experience of DM <9.1 years, DP <3.8 years, depression score <25 points and pain intensity (VAS) <5.6 points.
Conclusion.
Our study suggests that complex treatment with venlafaxine or pipofezine may be a highly effective therapy for chronic NPand concomitant psychovegetative disorders (autonomous dysfunction, anxiety-depressive disorder), though pipofezine has a morefavourable safety profile. Optimal regime for complex treatment is pipofezine 75 mg/day (in three doses) or venlafaxine 800 mg/dayin four doses.

diabetic polyneuropathy, neuropathic pain, anxiety, depression, venlafaxine, pipofezine, carbamazepine

1. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006 Jul;29(7):1518-1522.

2. Chong MS, Bajwa ZH. Diagnosis and treatment of neuropathic pain. J Pain Symptom Manage. 2003 May;25(5 Suppl):S4-S11.

3. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005 Dec 5;118(3):289-305. Epub 2005 Oct 6.

4. Pelissolo A. Depression and pain: prevalence and clinical implication. Presse Med. 2009 Mar;38(3):385-391. Epub 2008 Nov 1.

5. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005 Jun;96(6):399-409.

6. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001133.

7. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebocontrolled study. Eur J Pain. 2005 Oct;9(5):543-554. Epub 2004 Dec 18.

8. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs. 2007;67(4):569-585.

9. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975 Sep;1(3):277-299.

10. Ханин ЮЛ. Краткое руководство к применению шкалы реактивной и личностной тревожности Спилбергера ЧД. Л; 1976. 18 с.

11. Beck AT, Ward CM, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-571.

12. Вейн АМ. Заболевания вегетативной нервной системы. М; 1991. 624 с.

13. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun- Overdyking A, Jafari-Schluep H, Lant éri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesion and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005 Mar;114(1-2):29-36. Epub 2005 Jan 26.

14. Sullivan SD, Lew DP, Devine EB, Hakim Z, Reiber GE, Veenstra DL. Health state preference assessment in DPN. Pharmacoeconomics. 2002;20(15):1079-1089.

15. Quattrini C, Tesfaye S. Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev. 2003 Jan-Feb;19 Suppl 1:S2-8.

16. Болевые синдромы в неврологической практике. Под ред. Вейна АМ. М: МЕДпресс-информ; 2001. 368 с.

17. Presley RW, Cousins MJ. Current concepts in chronic pain management. Current Therapeutics. 1992;18: 51-60.

18. Jensen TS, Backonja MM, Hernández Jiménez S, Tesfaye S, Valensi P, Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res. 2006 Sep;3(2):108-119.

19. Jann MW, Slade JH. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy. 2007 Nov;27(11):1571-1587.

20. Андреева НИ, Аснина ВВ, Либерман СС. Отечественные антидепрессанты. Азафен. Хим. фармацевтич. журн. 2000;5:16-20.